PLx Pharma Inc. (PLXP)

PLx Pharma (NASDAQ: PLXP ) stock continues to fall on Wednesday as the company gets closer to being delisted from the Nasdaq Exchange . An update from PLx Pharma revealed that the Nasdaq is not giving it another 180-day period to regain compliance with listing rules.

PLx Pharma (NASDAQ: PLXP ) stock is taking a beating on Tuesday and there's a couple of reasons investors will want to know about its fall. First off, traders will keep in mind that PLXP stock underwent a massive rally on Monday.

Can these tips help you make money with penny stocks in 2023? The post Spotting Winning Penny Stocks: 3 Top Tips  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

PLx Pharma Inc. (NASDAQ:PLXP ) Q3 2022 Earnings Conference Call November 11, 2022 8:30 AM ET Company Participants Natasha Giordano - President, Chief Executive Officer Rita O'Connor - Chief Financial Officer Asif Ali - Preventative Cardiologist Janet Barth - Vice President, Investor Relations Conference Call Participants Leland Gershell - Oppenheimer Jason Butler - JMP Securities Operator Ladies and gentlemen, thank you for standing by and welcome to PLx Pharma's third quarter 2022 earnings conference call. At this time, all participants are in a listen-only mode.

PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 15.91% and 35.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that it will release its third quarter 2022 financial results before the open of the U.S. financial markets on Friday, November 11, 2022.

PLx Pharma Inc. (NASDAQ:PLXP ) Q2 2022 Earnings Conference Call August 12, 2022 8:30 AM ET Company Participants Janet Barth - Vice President, Investor Relations & Corporate Communications Natasha Giordano - President & Chief Executive Officer Rita O'Connor - Chief Financial Officer & Head, Manufacturing & Supply Chain Asif Ali - Preventative Cardiologist Conference Call Participants Jason Butler - JMP Securities Leland Gershell - Oppenheimer Elliot Wilbur - Raymond James Operator Hello, ladies and gentlemen. Thank you for standing by and welcome to the PLx Pharma Second Quarter 2022 Earnings Conference Call.

PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 7.14% and 86.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PLx Pharma Inc. (NASDAQ:PLXP ) Q1 2022 Earnings Conference Call May 13, 2022 8:30 AM ET Company Participants Natasha Giordano - President, Chief Executive Officer Rita O'Connor - Chief Financial Officer Mike Valentino - Executive Chairman Asif Ali - Preventative Cardiologist Janet Barth - Vice President, Investor Relations Conference Call Participants Leland Gershell - Oppenheimer Elliot Wilbur - Raymond James Jason Butler - JMP Securities Operator Ladies and gentlemen, thank you for standing by and welcome to PLx Pharma's first quarter 2022 earnings conference call. At this time, all participants are in a listen-only mode.

PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 4.35% and 11.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

SPARTA, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that it will release its 2022 first quarter financial results before the opening of the U.S. financial markets on Friday, May 13, 2022. Company executives will host a conference call at 8:30am ET that day with institutional investors and analysts to provide an overview of PLx Pharma's performance for the quarter, along with a business update.

PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q4 2021 Results - Earnings Call Transcript

Dipexium Pharmaceuticals, Inc. (PLXP) delivered earnings and revenue surprises of -5.80% and 17.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

SPARTA, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that Natasha Giordano, President and CEO of PLx Pharma Inc. and Rita O'Connor, Chief Financial Officer & Head of Manufacturing & Supply Chain, will present on March 15, 2022, at Oppenheimer & Co's 32nd Annual Healthcare Conference, which will be a virtual event this year.

SPARTA, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that it will release its 2021 fourth quarter financial results before the opening of the U.S. financial markets on Friday, March 11, 2022. Company executives will host a conference call at 8:30am ET that day with institutional investors and analysts to provide an overview of PLx Pharma's performance for the quarter, along with a business update.

Investors need to pay close attention to Dipexium Pharmaceuticals (PLXP) stock based on the movements in the options market lately.